Nuvation Bio/$NUVB
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Nuvation Bio
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
- Ticker
- $NUVB
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 305
- Headquarters
- New York, United States
- Website
- www.nuvationbio.com
Nuvation Bio Metrics
BasicAdvanced
$1.6B
-
-$0.44
1.53
-
Price and volume
Market cap
$1.6B
Beta
1.53
52-week high
$9.75
52-week low
$3.36
Average daily volume
5.4M
Financial strength
Current ratio
8.373
Quick ratio
7.984
Long term debt to equity
1.559
Total debt to equity
1.64
Interest coverage (TTM)
-5.16%
Profitability
EBITDA (TTM)
-135.481
Gross margin (TTM)
88.18%
Net profit margin (TTM)
-88.19%
Operating margin (TTM)
-81.00%
Revenue per employee (TTM)
$560,000
Management effectiveness
Return on assets (TTM)
-12.36%
Return on equity (TTM)
-47.81%
Valuation
Price to revenue (TTM)
8.946
Price to book
6.13
Price to tangible book (TTM)
6.39
Price to free cash flow (TTM)
-11.789
Free cash flow yield (TTM)
-8.48%
Free cash flow per share (TTM)
-0.377
Growth
Revenue change (TTM)
1,083.56%
Earnings per share change (TTM)
-29.33%
3-year earnings per share growth (CAGR)
1.98%
What the Analysts think about Nuvation Bio
Analyst ratings (Buy, Hold, Sell) for Nuvation Bio stock.
Analyst projections of the future price of Nuvation Bio stock.
Bulls say / Bears say
The FDA-approved label now reports a median duration of response of 49.7 months for TKI-naïve patients in TRUST-I, with no new safety signals after longer follow-up. That gives IBTROZI a compelling durability profile in its approved market. (Nuvation Bio)
IBTROZI generated $23.2 million in US product revenue in Q2 2026, up 25% from the prior quarter, and about 85% of new prescriptions were for patients who had not previously received a ROS1-targeted drug. The company also said it led new-patient starts among ROS1 inhibitors in the first five months of 2026. (Nuvation Bio)
Safusidenib offers a second potential growth driver: in a 27-patient Phase 2 study, the response rate was 51.9% and the 36-month progression-free survival rate was 79.1%. Nuvation is advancing the drug in new studies across additional IDH1-mutant glioma settings. (Nuvation Bio)
Management said the initial pool of previously treated patients had been largely worked through and new starts were easing. Continued growth therefore depends more on winning first-line patients and expanding the market. (EarningsCalls.dev)
Growth also faces practical barriers: management said ROS1 testing in some community settings can be as low as 30–40%, and immunotherapy or chemotherapy is still used despite guidance favouring targeted treatment. These habits could slow the number of eligible patients reaching IBTROZI. (EarningsCalls.dev)
The company remains loss-making despite rising sales: Q2 revenue was $31.7 million, while operating expenses were $73.3 million and the net loss was $62.8 million. Sustained commercial growth will need to cover substantial research and launch spending before profitability is established. (Nuvation Bio, The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2026.
Nuvation Bio Financial Performance
Revenues and expenses
Nuvation Bio Earnings Performance
Company profitability
Upcoming events
No upcoming events
Nuvation Bio News
AllArticlesVideos
Funds containing Nuvation Bio
Fund name | Fund size | $NUVB weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 0.12% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.12% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.12% |
iShares Ageing Population$AGED | $953M | 0.11% |
iShares Ageing Population€AGED | $903M | 0.11% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.